Therapeutic Relevance

Early experimental results strongly support the autophagy activation hypothesis. Two novel molecular targets identified (Autophagy1/Autophagy2 families) with commercially available compounds validated as potent inducers. Three rounds of NCE synthesis show 10-100x potency improvements over earlier series. The cell-based assay system (Npc1-/- vs Atg5-/-) effectively distinguishes true autophagy activators. FDA pilot screen validated platform by identifying 12 previously unknown autophagy inducers. Mechanism connecting autophagy deficiency to NAD+ depletion and cell death is well-established across species.

Therapeutic Optionality

Multiple therapeutic pathways emerging: primary indication NPC (orphan disease with shorter approval path), broader LSDs (~1 in 5,000 births), and major neurodegenerative diseases (Alzheimer's, Parkinson's where lysosomal dysfunction is prevalent). Longevity/aging applications represent universal population. Platform potential extends to metabolic diseases and potentially cancer. Dual development paths identified - novel NCEs and drug repurposing with Phase 1-tested molecules.

Intellectual Property

Strong IP position developing. Patent filed December 2025 for repurposed compounds for autophagy induction/longevity. Novel compound structures distinct from existing autophagy modulators (mTOR inhibitors). High chemical variability in screened molecules suggests novel IP potential. Two newly identified targets represent novel MOA. VitaFast LLC formed to manage IP. Additional patent applications planned for novel compounds following SAR optimization. Favorable FTO assessment against rapamycin/rapalogs and existing NPC therapies.

Utility Of Candidates

Three lead structures producing favorable NCEs with 10-100x higher potency than earlier series. Two repurposing molecules already through Phase 1 trials show high potency in autophagy assays. Commercially available compounds binding novel targets validated. Candidates demonstrate mechanism-specific rescue (work in Npc1-/- but not Atg5-/- cells). Manufacturing route established through contracted chemistry suppliers with SAR-driven optimization. Dual pathway (novel NCEs toward IND + repurposing toward clinical trial) de-risks development.

Prospects For Safety

Early safety signals are encouraging but limited. Lead compounds show no acute cytotoxicity at therapeutic concentrations in cellular assays. Mechanism specificity demonstrated (rescue only in autophagy-competent cells). However, formal safety studies not yet conducted. Worm healthspan/longevity studies ongoing. Murine safety experiments planned as IND-enabling activities. Repurposed compounds have Phase 1 safety data as advantage. Standard ADMET profiling and GLP toxicology package planned but not completed.